Valuation: AlzeCure Pharma AB

Market Cap 783M 76.68M 69.84M 64.36M 58.54M 110M 7.1B 115M 311M 3.88B 288M 282M 12.17B P/E 2026 *
-
P/E 2027 * -
Enterprise Value 783M 76.68M 69.84M 64.36M 58.54M 110M 7.1B 115M 311M 3.88B 288M 282M 12.17B EV / Sales 2026 *
4.51x
EV / Sales 2027 * 3.63x
Free-Float
62.51%
Yield 2026 *
-
Yield 2027 * -
1 day-2.74%
1 week-11.25%
Current month-11.25%
1 month-17.92%
3 months-11.53%
6 months+307.17%
Current year+184.00%
1 week 5.62
Extreme 5.62
6.68
1 month 5.52
Extreme 5.52
6.8
Current year 1.3
Extreme 1.3
8.68
1 year 1.3
Extreme 1.3
8.68
3 years 0.81
Extreme 0.812
8.68
5 years 0.81
Extreme 0.812
8.68
10 years 0.81
Extreme 0.812
12.1
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer 59 2016-12-31
Chief Executive Officer 56 2026-10-26
Director of Finance/CFO 59 2016-12-31
Director TitleAgeSince
Director/Board Member 73 2024-05-13
Chairman 73 2016-12-31
Director/Board Member 73 2016-12-31
Date Insider Type Main position Quantity % Market Cap. Importance
7/2/26 Buy

Chief Executive Officer

184,914 0.1341%
7/1/26 Buy

Founder

194,940 0.1414%
6/30/26 Buy

Chairman

240,625 0.1745%
Change 5-day change 1-year change 3-year change Capi.($)
-2.74%-11.25%+187.59%+45.27% 76.68M
-2.49%-3.76%+53.38%+62.10% 63.66B
-0.63%-2.91%+6.55%+89.34% 58.56B
-2.37%-2.22%+21.77%+84.58% 54.19B
-2.19%-6.15%+12.43%+111.40% 44.66B
-1.89%-7.28%+9.30%+18.50% 40.51B
-0.93%-0.47%+19.34%+41.83% 36.27B
+1.11%-6.44%+127.46%+675.37% 34.87B
-0.80%+0.61%+76.27%+61.80% 32.26B
-2.17%+16.65%-28.89%+479.93% 31.01B
Average -1.51%-2.22%+48.52%+167.01% 40B
Weighted average by Cap. -1.48%-1.85%+31.86%+155.12%

Financials

2026 *2027 *
Net sales 174M 16.99M 15.47M 14.26M 12.97M 24.33M 1.57B 25.57M 68.96M 859M 63.73M 62.39M 2.7B 216M 21.13M 19.24M 17.73M 16.13M 30.26M 1.96B 31.8M 85.77M 1.07B 79.27M 77.6M 3.35B
Net income 91.9M 9M 8.19M 7.55M 6.87M 12.89M 833M 13.54M 36.53M 455M 33.76M 33.05M 1.43B 141M 13.8M 12.57M 11.59M 10.54M 19.77M 1.28B 20.78M 56.04M 698M 51.79M 50.7M 2.19B
Net Debt - -
Projected Income Statement - Annual - AlzeCure Pharma AB
Logo AlzeCure Pharma AB
AlzeCure Pharma AB is a Sweden-based pharmaceutical research and development company with a primary focus on Alzheimer’s disease and other brain disease indications. The Company develops five drug candidates within its two main research programs, NeuroRestore and Alzstatin. The drug candidates in NeuroRestore stimulate a central signaling pathway in the brain that is essential for the functioning of nerve cells and has a strong genetic link to cognitive disorders, such as Alzheimer's disease. The main drug candidate, ACD855, is an already approved veterinary medicine available for the treatment of central nervous system (CNS) indications in animals and has undergone preclinical trials for human indications of impaired cognitive disorders. Alzstatin focuses on reducing the production of toxic amyloid beta (Aβ) protein in the brain. Aβ plays a central role in the pathology of Alzheimer’s disease and starts to accumulate in the brain many years before the first symptoms are recognized.
Employees
10
Date Price Change Volume
26-11-20 SEK 5.680 -2.74% 235,331
26-11-19 SEK 5.840 -4.26% 232,893
26-11-18 SEK 6.100 -1.29% 135,135
26-11-17 SEK 6.180 -3.13% 278,385
26-11-16 SEK 6.380 -0.31% 185,835

Net sales - Rate of surprise

Rate of surprise - Net sales - Annual - AlzeCure Pharma AB
  1. Stock Market
  2. Stocks
  3. ALZCUR Stock